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Purpose or Objective: Owing to legitimate fears concerning 
potentially devastating complications, the treatment of head 
and neck cancer in previously irradiated patient has been 
based on surgery for the best cases and chemotherapy for the 
inoperable ones. We review our series of 84 routinely re-
(chemot)irradiated patients since 2000. 
 
Material and Methods: Patients : 84 consecutive patients, 
mean age 60.47, previously treated by radio(chemo)therapy 
with a median delay between the the two irradiations of 36.3 
months have been treated. 54 patients with relapses and 30 
patients presenting second cancers . The mean follow-up is 
66.45 months.  
Methods : 42 patients were operated upon, 
(chemo)radiotherapy being used postoperatively for poor 
prognostic factors. 42 inoperable patients have been treated 
exclusively by radiochemotherapy. Before 2007, patients 
were treated by 2D techniques then by IMRT. 44 received 
concomitant platinum-based chemotherapy, 23 cetuximab 
and 17 radiotherapy alone. 
 
Results: Results : median overall survival for the entire 
population is 19.61 months. Specific survival 23 
months.Death causes : 40 the cancer itself, 9 patients 
complications et 11 other causes. Prognostic factors : age, 
sexe, performance status, Charlson score, location, type of 
resurgence (local, nodal or both), surgery, chemotherapy 
antecedents, type of concomitant treatment during the 
reirradiation, previous disabilities (tracheostomy, nasogastric 
tube) have been investigated. Only the type of resurgence is 
discriminant with a median survival time of 16.49 months for 
patients treated for a relapse and 32 months for those 
treated for a second cancer (Logrank p=0.00464). 
Complications : 9 deceased : 1 carotid blowout (with 
evolutive tumor), 3 late pneumoniae (patient NED), 3 
tumoral hemorrhages (evolutive tumors) and 2 unknown 
complications. Late sequellae: 10 radionecrosis (7 
osteoradionecrosis), 7 persistant dysphagia, 8 long term 
fistulas. 
 
Conclusion: Conclusion :The survival in our series restricted 
to the second cancers is similar to that obtained in not 
previously irradiated patients and confirm some data of the 
literature. Thereby it is our belief that, if the acceptance of 
this strategy of treatment may merit further clinical trials for 
the relapsing tumor (however the results compare favorably 
with palliative chemotherapy), it becomes unethical not to 
give this chance for the second cancers in spite of the risk of 
severe complication. 
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Purpose or Objective: the purpose of this study was to 
investigate the prognostic implication of adjuvant external 
beam radiation therapy on the locoregional control in 
patients with either locally advanced thyroid papillary 
carcinoma or cervical lymph node involvement. 
 
Material and Methods: retrospective analysis was performed 
on 165 patients with locally advanced thyroid papillary 
carcinoma (T4) or cervical lymph node involvement (N1b), 
who were treated between 2002 and 2011. Of these, 32 
patients were treated with total thyroidectomy followed by 
adjuvant external beam radiation therapy and radioactive 
iodine treatment, and 133 patients were treated with total 
thyroidectomy followed by radioactive iodine treatment. 
 
Results: The median follow-up time was 223 months (range, 
93 to 421 months). The 10-year disease-free survival and 
locoregional relapse-free survival rates were significantly 
better than unirradiated controls. 10-year disease-free 
survival rates for patients in the radiation therapy and no 
radiation therapy groups were 84.3% and 56.7%, respectively 
(p = 0.049). 10-year locoregional relapse-free survival rates 
for patients in the radiation therapy and no radiation therapy 
groups were 83.9% and 60.8%, respectively (p = 0.037). The 
overall survival rate and distant relapse-free survival rate 
were not different between the two groups. Multivariate 
analysis showed that adjuvant radiation therapy was an 
independent prognostic factor for locoregional relapse-free 
survival (p = 0.044). 
 
Conclusion: adjuvant external beam radiation therapy should 
be considered in patients with either pT4 disease or cervical 
lymph node involvement. 
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Purpose or Objective: Highly conformal dose distributions 
produced by rotational IMRT reliably delivered with daily 
IGRT raise the possibility that radical chemoIMRT for 
oropharyngeal carcinoma could be delivered in fewer 
fractions (#) for certain subgroups. The purpose of this study 
was to compare two cohorts of patients with oropharyngeal 
carcinoma treated within a single centre: the first treated 
with a 20# (4 weeks(wk)) schedule, the second with 25-35# 
(5-7wk) schedules. 
 
Material and Methods: Patients undergoing radical 
chemoIMRT between June 2009 and May 2012 were treated 
with 55Gy/20# over 25 days to PTV1 with synchronous 
carboplatin or cetuximab (20# cohort). Similar patients were 
treated between June 2012 and April 2014 with one of three 
schedules 64Gy/25# over 32 days, 65Gy/30# over 39 days or 
70Gy/35# over 46 days to PTV 1 with synchronous cisplatin or 
cetuximab (25-35# cohort). The local control (LC) and overall 
survival (OS) of these two cohorts were compared using the 
log-rank test. 
 
Results: The minimum time elapsed from treatment in all 
patients was 18 months. There were 86 patients in the 20# 
cohort: median age 58 years; p16+ 60 (70%); T4 28 (33%); 
N2C/N3 16 (19%). There were 77 patients in the 25-35# 
cohort: median age 59 years; p16+ 54 (70%); T4 24 (32%); 
N2C/N3 16 (22%). The 18 month local control in the two 
cohorts respectively was 86% v. 88% (p=0.69). The 18 month 
overall survival was 85% v. 89% (p=0.41). If the two cohorts 
were restricted to those patients who were p 16+ve, T1-3, no 
neo-adjuvant chemotherapy and platinum agent used 
synchronously the corresponding figures (n= 26 for 20# cohort 
v. n=38 for 25-35# cohort) for local control were 92% v. 95% 
(p=0.34) and for overall survival 96% v 100% (p=0.22). 
 
Conclusion: Although further follow up and late toxicity data 
is required, the similarity in results seen between the two 
cohorts in this study warrant the testing of the 20# schedule 
with synchronous cisplatin in a randomised setting in good 
prognosis oropharyngeal patients. This similarity in the 
endpoints studied is evidence against synchronous 
chemotherapy acting to reduce accelerated repopulation 
